Novel therapies, including enzastaurin, in the treatment of ovarian cancer

Bibliography

• Ovarian cancer statistics. Centers for Disease Control and Prevention. 2012. Available from: http://www.cdc.gov/cancer/ovarian/statistics/index.htm [Last accessed 4 February 2014]
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Ovarian Cancer. National Cancer Institute. 2013. Available from: http://www.cancer.gov/cancertopics/types/ovarian [Last accessed 4 February 2014]
   Google Scholar
• Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943-53
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W, et al. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320-9
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699-708
   PubMed Web of Science ®Google Scholar
• Diaz-Montes TP, Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep 2005;7(6):451-8
   PubMedGoogle Scholar
• Stuart GC, Kitchener E, Bacon H, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21(4):750-5
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Armstrong DK, Brady MF, et al. Ovarian cancer clinical trial endpoints: society of Gynecologic Oncology white paper. Gynecol Oncol 2014;132(1):8-17
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Isonishi S, et al. Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled open-label trial. Lancet Oncol 2013;14(10):1020-6
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks or advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374(9698):1331-8
   PubMed Web of Science ®Google Scholar
• Burg ME, Janssen JT, Ottevanger PB, et al. Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC) [abstract 5538]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Pignata S, Scambia G, Lauria R, et al. A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)—European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. J Clin Oncol 2013;31(Suppl):abstract LBA5501
   Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115(6):1234-44
   PubMed Web of Science ®Google Scholar
• Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009;27(4):1419-25
   PubMedGoogle Scholar
• Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006;24(28):4528-30
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044-56
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Fuse N, et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71(1):227-35
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30(4):362-71
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. LATE BREAKING ABSTRACT: A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. Eur J Cancer 2013;49(Suppl):abstract 41
   Google Scholar
• TRI-NOVA-2: trebananib in ovarian cancer-2. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT01281254 [Last accessed 27 January 2014]
   Google Scholar
• TRI-NOVA-3: a study of AMG 386 or AMG 386 placebo in combination with paclitaxel and carboplatin to treat ovarian cancer. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT01493505 [Last accessed 17 February 2014]
   Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Oza AM, Perren TJ, Swart AM, et al. Late breaking abstract: ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013;49(Suppl):abstract 6
   Google Scholar
• Pujade-Lauraine E, Hipert F, Weber P, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl):abstract LBA5002
   Google Scholar
• Witteveen P, Lortholary A, Fehm T, et al. LATE BREAKING ABSTRACT: Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013;49(Suppl):abstract 5
   Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45
   PubMed Web of Science ®Google Scholar
• Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011;5:1-5
   PubMedGoogle Scholar
• Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008;9(12):1324-35
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gonzalez-Martin A, García Y, et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) study. J Clin Oncol 2012;30(Suppl):abstract 5068
   Google Scholar
• Du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 2013;13(Suppl):abstract LBA5503
   Google Scholar
• Pazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. ClinicalTrials.gov. 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01402271 [Last accessed 4 September 2013]
   Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-82
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29(28):3798-804
   PubMed Web of Science ®Google Scholar
• du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-INTERGROUP phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(8):abstract
   Google Scholar
• ENGOT Trials. European Society of Gynaecological Oncology. 2013. Available from: http://www.esgo.org/engot/Pages/ENGOTTrials.aspx [Last accessed 4 September 2013]
   Google Scholar
• Dantzer F, de La Rubia G, Menissier-De Murcia J, et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000;39(25):7559-69
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009;3(2):138-50
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123-34
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245-51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase II open label, randomized, multicentre study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor to pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-9
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 2011;29(Suppl 15):abstract 5003
   Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 2013;31(Suppl 15):abstract 5505
   Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12(9):852-61
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13(9):2728-37
   PubMed Web of Science ®Google Scholar
• A trial of ABT-888 in combination with temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer. ClinicalTrials.gov. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01113957 [Last accessed 4 September 2013]
   Google Scholar
• ABT-888 with cyclophosphamide in refractory BRCA-positive ovarian, primary peritoneal or ovarian high-grade serous carcinoma, fallopian tube cancer, triple-negative breast cancer, and low-grade non-Hodgkin’s lymphoma. ClinicalTrials.gov. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01306032 [Last accessed 4 September 2013]
   Google Scholar
• Veliparib in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. ClinicalTrials.gov. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01540565 [Last accessed 15 May 2013]
   Google Scholar
• Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009;52(22):7170-85
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013;14(9):882-92
   PubMed Web of Science ®Google Scholar
• A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT01847274 [Last accessed 4 September 2013]
   Google Scholar
• Shen Y, Feng Y, Wang B, et al. LT-00673, a highly potent PARPIs, shows antitumor activity against tumor cells with DNA repair deficiencies. [Poster:4098] Presented at the American Association for Cancer Research Annual Meeting; 17-21 April 2010; Washington, DC
   Google Scholar
• Study of BMN 673, a PARP inhibitor, in patients with advanced or recurrent solid tumors. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT01286987 [Last accessed 4 September 2013]
   Google Scholar
• Wang DD, Kern KA, Carpentieri M, et al. Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients. J Clin Oncol 2011;29(Suppl):abstract e13615
   Google Scholar
• Molife LR, Roxburgh P, Wilson RH, et al. A phase I study of oral rucaparib in combination with carboplatin. J Clin Oncol 2013;31(Suppl):abstract 2586
   Google Scholar
• Kristeleit RS, Shapiro G, LoRusso P, et al. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol 2013;31(Suppl):abstract 2585
   Google Scholar
• Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338(2):284-93
   PubMed Web of Science ®Google Scholar
• Miotti S, Bagnoli M, Ottone F, et al. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65(4):479-91
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6
   PubMedGoogle Scholar
• Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 2010;11(12):1424-33
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16(21):5288-95
   PubMed Web of Science ®Google Scholar
• White AJ, Coleman RL, Armstrong DK, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. J Clin Oncol 2010;28(Suppl 15):abstract 5001
   Google Scholar
• An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer (FAR-122). ClinicalTrials.gov. 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00738699 [Last accessed 4 September 2013]
   Google Scholar
• Efficacy and safety of MORAb-003 in subjects with platinum-sensitive ovarian cancer in first relapse. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT00849667 [Last accessed 4 September 2013]
   Google Scholar
• Reddy JA, Bloomfield A, Nelson M, et al. Combination studies of EC145 with approved anti-cancer drugs for ovarian cancer. Cancer Res 2011;71(Suppl 8):abstract 2570
   Google Scholar
• Naumann RW, Coleman RL, Burger RA. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2011;29(Suppl 15):abstract 5045
   Google Scholar
• Study for women with Platinum Resistant Ovarian Cancer Evaluating EC145 in combination with Doxil® (PROCEED). ClinicalTrials.gov. Available from: http://clinicaltrial.gov/ct2/show/NCT01170650 [Last accessed 5 February 2014]
   Google Scholar
• Miller CR, Oliver KE, Farley JH. MEK 1/2 inhibitors in the treatment of gynecologic malignancies. Gyn Oncol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm phase 2 study. Lancet Oncol 2013;14:134-40
   PubMed Web of Science ®Google Scholar
• A study of MEK162 vs. physician’s choice chemotherapy in patients with low-grade serous ovarian, fallopian tube or peritoneal cancer. ClinicalTrials.gov. 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01849874?term=NCT01849874 [Last accessed 28 January 2014]
   Google Scholar
• Study of MEK162 and paclitaxel in patients with epithelial ovarian, fallopian tube or peritoneal cancer. ClinicalTrials.gov. 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01649336?term=NCT+01649336 [Last accessed 28 January 2014]
   Google Scholar
• Trial of pimasertib with SAR245409 or Placebo in ovarian cancer. ClinicalTrials.gov. 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01936363?term=NCT01936363 [Last accessed 28 January 2014]
   Google Scholar
• Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 2003;13(11):1857-9
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002;99(2):721-6
   PubMed Web of Science ®Google Scholar
• Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98(9):2018-26
   PubMed Web of Science ®Google Scholar
• Aeder SE, Martin PM, Soh JW, et al. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 2004;23(56):9062-9
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 279:47720-5.2004
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-63.2004
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8(3):187-98
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65(16):7462-9
   PubMed Web of Science ®Google Scholar
• Bräutigam K, Bauerschlag DO, Weigel MT, et al. Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. Transl Oncol 2009;2(3):164-73
   PubMed Web of Science ®Google Scholar
• Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53(2):133-40
   PubMed Web of Science ®Google Scholar
• Cadron I, Van Gorp T, Mihalyi A, et al. The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. Gynecol Oncol 2010;118(1):64-8
   PubMed Web of Science ®Google Scholar
• Camidge DR, Gail Eckhardt S, Gore L, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008;19(1):77-84
   PubMedGoogle Scholar
• Welch P, Musib L, Darstein C, et al. Effects of a proton pump inhibitor (lansoprazole) and food on the bioavailability of enzastaurin administered as single oral doses to healthy subjects. J Clin Oncol 2007;25(Suppl 18):abstract 14076
   Google Scholar
• Welch PA, Sinha VP, Cleverly AL, et al. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol 2007;47(9):1138-51
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24(25):4092-9
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25(13):1741-6
   PubMed Web of Science ®Google Scholar
• Rademaker-Lakhai JM, Beerepoot LV, Mehra N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007;13(15 Pt 1):4474-81
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;20(9):1565-75
   PubMed Web of Science ®Google Scholar
• Vergote I, Amant F, Oskay-Oezcelik G, et al. Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. Int J Gynecol Cancer 2009;19(9):1505-10
   PubMed Web of Science ®Google Scholar
• Usha L, Sill MW, Darcy KM, et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011;121(3):455-61
   PubMed Web of Science ®Google Scholar
• Vergote I, Chekerov R, Amant F, et al. Randomized, phase 2, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment, followed by maintenance treatment in advanced ovarian cancer. J Clin Oncol 2013;31(25):3127-32
   PubMed Web of Science ®Google Scholar
• Nwankwo N, Zhang Z, Wang T, et al. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs 2013;31(3):653-60
   PubMed Web of Science ®Google Scholar
• Evaluation of enzastaurin in the treatment of persistent or recurrent ovarian or primary peritoneal cancer. ClinicalTrials.gov. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT00420381 [Last accessed 27 January 2014]
   Google Scholar
• Dreicer R, Garcia J, Rini B, et al. A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Invest New Drugs 2013;31(4):1044-50
   PubMed Web of Science ®Google Scholar
• Padda SK, Krupitskaya Y, Chhatwani L, et al. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;69(4):1013-20
   PubMed Web of Science ®Google Scholar
• Chiappori A, Bepler G, Barlesi F, et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5(3):369-75
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Arrowsmith ER, McCleod M, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): preliminary analysis. J Clin Oncol 2011;29(Suppl):abstract 8016
   Google Scholar
• Querfeld C, Kuzel TM, Kim YH, et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma 2011;52(8):1474-80
   PubMed Web of Science ®Google Scholar
• Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005;23(Suppl):abstract 1504
   Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28(7):1168-74
   PubMed Web of Science ®Google Scholar
• Crump M, Leppä S, Fayad LE, et al. Phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial [abstract]. Blood 2013;122(21):371
   Google Scholar